Draghia-Akli Ruxandra 4/A

What Happened

Ruxandra Draghia-Akli, Executive VP of Research & Development at Novavax (NVAX), was granted a derivative award of 139,500 shares under the company’s equity plan on March 2, 2026. The reported acquisition price is $0.00, so no cash was paid at grant and the reported value is $0 for the acquisition entry. The Form 4 filed March 9, 2026 is an amendment correcting the exercise/derivative price originally reported.

Key Details

• Transaction date: March 2, 2026; Form 4 originally filed March 5, 2026 and amended March 9, 2026 to correct price (footnote F1).
• Transaction type/code: Award/Grant (A) of a derivative security; reported acquisition price $0.00; reported aggregate cash value $0.
• Vesting: 1/4 vests on the first anniversary of March 2, 2026; remaining 3/4 vest in equal monthly installments over the following three years, subject to continued employment (footnote F2).
• Shares owned after transaction: Not specified in the provided filing.
• No sale or immediate disposition reported; this is a time-vesting award, not a market purchase or sale.

Context

This is a grant of a derivative equity award (commonly RSUs or options under the company plan) that vests over four years; the recipient does not immediately receive fully transferable shares or cash. The amended filing corrects previously reported price information but does not change the substance of the grant. Grants are a common form of executive compensation and do not by themselves indicate a near-term buy or sell decision.